Xinyun Medical Secures Nearly RMB 10 Million Pre-A Investment from Legend Star to Empower Primary Care Pain Clinics

Recently, Xinyun Medical announced that it had secured nearly RMB 10 million in Pre-A round financing from Legend Star. It is reported that in October 2016, Xinyun Medical received RMB 1.2 million in seed-round investment, and subsequently raised several million yuan more in December of the same year.

Zhao Yun, Founder and CEO of Xinyun Medical, stated that the healthcare services market is operation-intensive, and leveraging technological means to standardize operations and increase the proportion of effective operations poses a challenge for all institutions. Xinyun Medical’s differentiation lies in concentrating its superior resources on enhancing departmental operations in primary care pain management units. Meanwhile, Xinyun has developed a TaaS (Technology-as-a-Service) management platform for pain departments to standardize the operational management of primary care pain units. This platform features big data monitoring, aggregation, and BI analytics capabilities, and further enhances patients’ pain management experience through artificial intelligence.

On this platform, all hardware devices provided by Xinyun Medical to hospitals can be managed via the Internet of Things (IoT). The system systematically aggregates real-time device location, operational status, and patient disease management data to formulate effective departmental operation and management solutions. It also features an epidemiological survey module that tracks metrics such as the types, quantities, and incidence rates of pain patients across different regions.

Zhao Yun stated that neuromodulation devices under Xinyun Medical, such as physiotherapy instruments, are independently developed. The company also collaborates with major medical device manufacturers to co-develop products tailored for primary healthcare settings. To date, Xinyun Medical has signed service agreements with more than 60 hospitals.

From Zhao Yun’s perspective, the pain points facing primary-care pain management departments lie in shortages of physicians, funding, and equipment, as well as a lack of standardized experience in department establishment. This presents both an opportunity and a challenge. Compared with other specialties, pain medicine is a relatively new field; public awareness remains low, and relevant policies are still imperfect.

Zhao Yun revealed that New Cloud Medical plans to establish its own specialized hospital for pain management, which will serve as a base for physicians’ multi-site practice and clinical demonstration teaching. New Cloud Medical will also deepen its collaboration with the Jisheng Pain Medicine Foundation by launching charitable initiatives to alleviate poverty caused by illness. In terms of service scope, New Cloud Medical intends to expand from pain management into functional neurosurgery in the future.

It is reported that Xinyun Medical is headquartered in Beijing and was registered in June 2016. Currently, the company has a team of over 100 employees, with its core team possessing extensive experience in the healthcare industry. Notably, Zhao Yun, who serves as a key member, previously held the positions of Marketing Director at Hong Kong Ruijing Group and Vice President at Feihua Health Network, bringing nearly a decade of experience in the medical market. Furthermore, Xinyun Medical has garnered support from several renowned professors and experts in the field of pain management, including Han Jisheng, Fan Bifa, and Wu Shiming.

Zhao Yun stated that the investors in this round chose Legend Star primarily due to its high brand recognition, which is conducive to the future development and growth of Xinyun Medical. Moreover, Legend Star’s investment portfolio in the healthcare services sector will also bring new collaborative opportunities to Xinyun Medical.

Since its inception, Legend Star has prioritized healthcare as a key investment sector and remains the only early-stage investment firm with a systematic layout in this field. To date, it has invested in over 50 projects, including outstanding enterprises such as Tianjin MicroNano Core, Pacgen Biopharma, Kintor Pharmaceutical, Cayody Biotech, Yu Ying Medical, and Zhi Kang Bo Yao. In the healthcare sector, Legend Star’s strategic layout focuses on two major pillars: new technologies and new services. New technologies encompass novel biological drugs and therapies, gene technologies and services, diagnostic technologies, and high-value consumables. New services include diagnostic/data terminals deployable at the grassroots level, innovations in healthcare service delivery, and optimization of medical resource allocation. Legend Star will continue to focus on the healthcare sector and invest in more high-quality projects.